RX-3341
A Randomized, Double-blind, Multi-center Study of the Safety and Efficacy of
RX 3341 compared with Cefazolin for the Prevention of Surgical Site Infections following Coronary Artery Bypass Graft Surgery (CABG)

Sponsor: Rib-X Pharmaceutical Inc

Investigator: Todd Dewey, MD*
                  William Brinkman, MD
                  James Edgerton, MD
                  Michael Mack, MD
                  Mitchell Magee, MD
                  David Moore, MD
                  William Ryan, MD

Research Coordinator: Victor Thothong, RN, BSN
                                 

Designated Site: The HEART HOSPITAL Baylor Plano


A double-blind, phase 3, multicenter study of RX-3341 compared with cefazolin used for the prevention of surgical site infections (SSIs) in patients undergoing sternotomy for CABG surgery.

 

* denotes Principal Investigator